X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (85361) 85361
Newsletter (5218) 5218
Newspaper Article (5133) 5133
Book Chapter (393) 393
Dissertation (157) 157
Web Resource (140) 140
Government Document (132) 132
Publication (81) 81
Magazine Article (67) 67
Conference Proceeding (62) 62
Reference (30) 30
Book / eBook (25) 25
Trade Publication Article (15) 15
Book Review (9) 9
Transcript (6) 6
Streaming Video (4) 4
Journal / eJournal (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50043) 50043
epidermal growth factor (39042) 39042
animals (27242) 27242
oncology (23537) 23537
female (22042) 22042
cancer (18347) 18347
male (15744) 15744
receptor, epidermal growth factor - metabolism (13887) 13887
research (13462) 13462
mice (13184) 13184
expression (12000) 12000
cell biology (11491) 11491
mutation (11452) 11452
middle aged (11177) 11177
biochemistry & molecular biology (10928) 10928
signal transduction (10811) 10811
proteins (9919) 9919
receptor, epidermal growth factor - genetics (9764) 9764
phosphorylation (9521) 9521
aged (9453) 9453
epidermal growth factor receptors (9367) 9367
tumors (9173) 9173
cell line, tumor (9017) 9017
adult (8760) 8760
epidermal-growth-factor (8657) 8657
breast cancer (8487) 8487
kinases (8397) 8397
chemotherapy (8249) 8249
epidermal growth factor receptor (8045) 8045
analysis (7722) 7722
lung cancer (7573) 7573
metastasis (7541) 7541
receptor, epidermal growth factor - antagonists & inhibitors (7489) 7489
egfr (7258) 7258
care and treatment (7144) 7144
gene expression (7123) 7123
genetic aspects (6956) 6956
epidermal growth factor - pharmacology (6889) 6889
growth-factor receptor (6859) 6859
apoptosis (6458) 6458
immunohistochemistry (6446) 6446
prognosis (6173) 6173
activation (6054) 6054
rats (6010) 6010
cells, cultured (5881) 5881
epidermal growth-factor (5573) 5573
cancer therapies (5550) 5550
epidermal growth factor - metabolism (5510) 5510
gefitinib (5397) 5397
tyrosine (5347) 5347
cell line (5299) 5299
research article (5139) 5139
health aspects (5021) 5021
cells (5000) 5000
patients (4921) 4921
medicine (4913) 4913
multidisciplinary sciences (4800) 4800
lung cancer, non-small cell (4681) 4681
antineoplastic agents - therapeutic use (4668) 4668
lung neoplasms - genetics (4430) 4430
cell proliferation (4429) 4429
lung neoplasms - drug therapy (4396) 4396
aged, 80 and over (4382) 4382
survival (4355) 4355
growth factors (4236) 4236
physiological aspects (3914) 3914
receptor (3888) 3888
therapy (3886) 3886
ligands (3804) 3804
tumor cells, cultured (3774) 3774
factor receptor (3768) 3768
studies (3746) 3746
signal transduction - drug effects (3699) 3699
oncology, experimental (3697) 3697
antineoplastic agents - pharmacology (3671) 3671
pathology (3656) 3656
pharmacology & pharmacy (3642) 3642
medical prognosis (3638) 3638
carcinoma, non-small-cell lung - drug therapy (3603) 3603
lung neoplasms - pathology (3573) 3573
medical research (3570) 3570
development and progression (3528) 3528
science (3408) 3408
receptors (3406) 3406
proliferation (3327) 3327
protein (3306) 3306
carcinoma (3301) 3301
egf receptor (3231) 3231
adenocarcinoma (3208) 3208
biology (3197) 3197
genes (3173) 3173
growth (3162) 3162
erlotinib (3149) 3149
molecular sequence data (3144) 3144
rodents (3144) 3144
breast neoplasms - pathology (3133) 3133
gene-expression (3125) 3125
medicine & public health (3116) 3116
treatment outcome (3110) 3110
cell proliferation - drug effects (3097) 3097
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (94844) 94844
Chinese (1083) 1083
Japanese (748) 748
French (395) 395
German (217) 217
Russian (196) 196
Korean (116) 116
Spanish (106) 106
Polish (44) 44
Hungarian (40) 40
Portuguese (33) 33
Czech (28) 28
Italian (23) 23
Bulgarian (10) 10
Dutch (10) 10
Danish (8) 8
Turkish (8) 8
Croatian (4) 4
Norwegian (4) 4
Persian (4) 4
Ukrainian (4) 4
Hebrew (3) 3
Lithuanian (3) 3
Romanian (3) 3
Serbian (3) 3
Finnish (2) 2
Swedish (2) 2
Arabic (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer science, ISSN 1347-9032, 2016, Volume 107, Issue 8, pp. 1134 - 1140
Journal Article
Nature (London), ISSN 1476-4687, 2014, Volume 508, Issue 7494, pp. 118 - 122
.... In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR... 
Antineoplastic Agents/administration & dosage | Transforming Growth Factor beta/metabolism | Humans | Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | Indoles/administration & dosage | Flow Cytometry | Receptor, Platelet-Derived Growth Factor beta/biosynthesis | Proto-Oncogene Proteins B-raf/antagonists & inhibitors | ErbB Receptors/biosynthesis | Melanoma/drug therapy | Female | Cell Proliferation/drug effects | Sulfonamides/administration & dosage | Gene Library | Cellular Senescence/drug effects | Receptor Protein-Tyrosine Kinases/biosynthesis | Drug Resistance, Neoplasm/drug effects | Gene Expression Regulation, Neoplastic/drug effects | SOXE Transcription Factors/deficiency | Signal Transduction/drug effects | Protein Kinase Inhibitors/administration & dosage | Vemurafenib | Animals | Mice | RNA, Small Interfering | GROWTH-FACTOR RECEPTOR | BRAF INHIBITOR | RAF INHIBITION | CELLS | MULTIDISCIPLINARY SCIENCES | IMPROVED SURVIVAL | DIFFERENTIATION | C-JUN | CANCER | EXPRESSION | EGFR | Receptor, Epidermal Growth Factor - genetics | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Melanoma - genetics | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | Patients | Tumors | Index Medicus
Journal Article
Cancer science, ISSN 1347-9032, 2016, Volume 107, Issue 7, pp. 1039 - 1046
...‐8201a is a human epidermal growth factor receptor 2 (HER2)‐targeting antibody–drug conjugate prepared using a novel linker... 
topoisomerase I inhibitor | T‐DM | HER2 | bystander killing | Antibody‐drug conjugate | T-DM | Antibody-drug conjugate | HODGKINS LYMPHOMA | GEMTUZUMAB OZOGAMICIN | ADVANCED BREAST-CANCER | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | TRASTUZUMAB EMTANSINE | CHALLENGES | THERAPY | ONCOLOGY | EXPRESSION | CATHEPSIN-B | Receptor, ErbB-2 - genetics | Breast Neoplasms - immunology | Humans | Ado-Trastuzumab Emtansine | Stomach Neoplasms - pathology | Maytansine - pharmacology | Immunoconjugates - immunology | Breast Neoplasms - enzymology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Neoplasms - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Camptothecin - immunology | Receptor, ErbB-2 - immunology | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Maytansine - analogs & derivatives | Neoplasms - enzymology | Stomach Neoplasms - immunology | Animals | Breast Neoplasms - genetics | Bystander Effect - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms - immunology | Cell Membrane Permeability - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | Neoplasms - pathology | Camptothecin - pharmacology | Maytansine - immunology | Trastuzumab | Viral antibodies | Epidermal growth factor | Imaging systems | Antibodies | Permeability | Drug therapy | Biopharmaceutics | Tumors | Antigens | Hematology | Laboratories | Toxicity | DNA topoisomerase | Polymerization | Clinical trials | Cytotoxicity | Breast cancer | ErbB-2 protein | Stomach cancer | Hypotheses | Antitumor agents | Xenografts | Antitumor activity | Lymphomas | Drug dosages | Payloads | Index Medicus | Original
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 58, Issue 1, pp. 155 - 168
.... Tight regulation of BA transporters via nuclear receptors is necessary to maintain proper BA homeostasis... 
Gastroenterology and Hepatology | Gallstones | Liver cancer | Bile acids | Fatty liver disease | Cholestasis | Liver regeneration | RAT-LIVER | SALT EXPORT PUMP | GROWTH-FACTOR 19 | ORGANIC ANION TRANSPORTERS | 90-PERCENT PARTIAL-HEPATECTOMY | URSODEOXYCHOLIC ACID | PRIMARY BILIARY-CIRRHOSIS | FARNESOID-X-RECEPTOR | GASTROENTEROLOGY & HEPATOLOGY | PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS | FAMILIAL INTRAHEPATIC CHOLESTASIS | Animals | Carrier Proteins - metabolism | Cholestasis - metabolism | Membrane Glycoproteins - metabolism | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Liver Diseases - metabolism | Liver Regeneration - physiology | Receptors, Cytoplasmic and Nuclear - metabolism | Drug resistance in microorganisms | Corticosteroids | Glucagon | Calcifediol | Ursodiol | Deoxycholic acid | Epidermal growth factor | Vitamin D | Physiological aspects | Fibroblast growth factors | Alfacalcidol | IBABP (FABP6, ILBP), intestinal bile acid-binding protein, fatty acid-binding protein 6 | PFIC, progressive familial intrahepatic cholestasis | TNFα, tumor necrosis factor α | 3 (human) | SRC2, p160 steroid receptor coactivator | NAFLD, non-alcoholic fatty liver disease | BA, bile acid | bile acid receptor | 8, cholesterol efflux pump, ATP-binding cassette, subfamily G, member 5 | UDCA, ursodeoxycholic acid | LRH-1 (NR5A2), liver receptor homolog-1 | LCA, lithocholic acid | LXRα (NR1H3), liver X receptor alpha | PPARγ (NR1C3), peroxisome proliferator-activated receptor gamma | OSTαβ, organic solute transporter alpha | ABCG5 | AMPK, AMP activated protein kinase | NASH, non-alcoholic steatohepatitis | SHP (NR0B2), short heterodimer partner | OATP1A2 (SLCO1A2, OATP1, OATP-A, SLC21A3), solute carrier organic anion transporter family, member 1A2 | EGFR, epidermal growth factor receptor | IL6, interleukin 6 | TGR5, G protein-coupled bile acid receptor | PH, partial hepatectomy | AE2, anion exchanger 2 | PSC, primary sclerosing cholangitis | OATP1B1 (SLCO1B1, OATP2, OATP-C, SLC21A6), solute carrier organic anion transporter family, member 1B1 | RARα (NR1B1), retinoic acid receptor alpha | GLP-1, glucagon like peptide 1 | VDR (NR1I1), vitamin D receptor. Please note that for the convenience of better readability and clarity, abbreviations for transporters and nuclear receptors were capitalized throughout this article when symbols were identical for human and rodents | MRP2 (ABCC2), multidrug resistance-associated protein 2, ATP-binding cassette, subfamily C, member 2 | NTCP (SLC10A1), sodium | CAR (NR1I3), constitutive androstane receptor | taurocholate cotransporting polypeptide, solute carrier family 10, member 1 | PPARα (NR1C1), peroxisome proliferator-activated receptor alpha | Review | GR (NR3C1), glucocorticoid receptor | Bile acids, Cholestasis, Fatty liver disease, Gallstones, Liver regeneration, Liver cancer | 19, fibroblast growth factor 15 | Mdr2 | ICP, intrahepatic cholestasis of pregnancy | BRIC, benign recurrent intrahepatic cholestasis | OATP1B3 (SLCO1B3, OATP8, SLC21A8), solute carrier organic anion transporter family, member 1B3 | MRP3 (ABCC3), multidrug resistance-associated protein 3, ATP-binding cassette, subfamily C, member 3 | beta | MDR1 (ABCB1), p-glycoprotein, ATP-binding cassette, subfamily B, member 1 | norUDCA, norursodeoxycholic acid | 6-ECDCA, 6-ethylchenodeoxycholic acid | FXR (NR1H4), farnesoid X receptor | BCRP (ABCG2), breast cancer resistance protein, ATP-binding cassette, subfamily G, member 2 | HNF4α (NR2A1), hepatocyte nuclear factor 4 alpha | PBC, primary biliary cirrhosis | MDR3 (ABCB4), multidrug resistance protein 2 (rodents) | HNF1α, hepatocyte nuclear factor 1 alpha | NR, nuclear receptor | FGF15 | RXRα (NR2B1), retinoid X receptor alpha | PXR (NR1I2), pregnane X receptor | BSEP (ABCB11), bile salt export pump | HCC, hepatocellular carcinoma | MRP4 (ABCC4), multidrug resistance-associated protein 4, ATP-binding cassette, subfamily C, member 4 | TPN, total parenteral nutrition
Journal Article
Nature (London), ISSN 1476-4687, 2015, Volume 526, Issue 7572, pp. 263 - 267
.... In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation(1... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors
Journal Article
Archives of pathology & laboratory medicine (1976), ISSN 1543-2165, 2014, Volume 138, Issue 2, pp. 241 - 256
Journal Article